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A b s t r A c t
Antiretroviral (ArV) therapy has dramatically reduced morbidity and mortality in human 
immunodeficiency virus 1 (HiV-1) infected children. However, development of ArV resistance in 
these children is a major public health problem due to lack of availability of and access to new 
drugs. this study was conducted in order to identify circulating HiV subtypes and recombinant 
forms and evaluate the drug resistance mutation patterns in 18 HiV-1 infected children failing 
ArV treatment in Kelantan, Malaysia. Genotyping for codon 1-99 of protease (Pr) and 1-250 of 
reverse transcriptase (rt) were performed by polymerase chain reaction (Pcr) amplification 
and DnA sequencing. subsequently, these were phylogenetically analyzed to determine the 
subtypes. crf33_01b (44.4%) was found to be the predominant HiV subtype, followed by b (27.8%), 
crf15_01b (16.7%) and crf01_AE (11.1%) subtypes. the most prevalent rt mutations were t215f/
V/Y (66.7%), D67G/n (55.6%), K219Q/E/r (44.4%), M184V/i (38.9%), K70r/E (27.8%) and M41L (27.8%), 
associated with nucleoside reverse transcriptase inhibitors (nrti) resistance; and K103n (55.6%), 
G190A (33.3%), and K101P/E/H (27.8%) associated with non-nucleoside reverse transcriptase 
inhibitors (nnrti) resistance. the results showed a possible emergence of crf33_01b as current 
predominant subtypes/circulating recombinant forms (crfs), and a high frequency of primary 
mutations among HiV-1 infected children after failure of ArV therapy in Kelantan, Malaysia.
Brief Communication
Assessing subtypes and drug resistance mutations among 
HIV-1 infected children who failed antiretroviral therapy in 
Kelantan, Malaysia
Suharni Mohamada,*, Zakuan Zainy Derisa, Nik Khairulddin Yusoffb, 
Tg Ahmad Akram Tg Mohd Ariffina, Rafidah Hanim Shueba 
aDepartment of Medical Microbiology and Parasitology, Universiti Sains Malaysia, Kubang Kerian, Kelantan, Malaysia 
bHospital Raja Perempuan Zainab II, Kota Bharu, Kelantan, Malaysia
*Corresponding author at: Department of Medical Microbiology & Parasitology, Health campus, school of Medical sciences,  
 Universiti sains Malaysia, 16150 Kubang Kerian, Kelantan, Malaysia 
 E-mail address: suharni5780@gmail.com (suharni Mohamad)
Introduction
in southeast Asia, 3.5 million people are living with human 
immunodeficiency virus/acquired immunodeficiency 
syndrome (HiV/AiDs), mostly in indonesia, Myanmar, nepal, 
and thailand. regionally, women constitute 37% of the 3.5 
million people living with HiV/AiDs, and about a third of 
infants born to HiV-positive mothers could acquire HiV. At 
the end of 2010, it was estimated that 150,000 children in south 
and southeast Asia were living with HiV.1 
Mother-to-child transmission (Mtct) is a significant HiV 
transmission route to children in Asia. ninety percent of 
Mtcts occur during late pregnancy, when maternal blood 
enters the fetal circulation, or during labor and delivery due 
to mucosal exposure to the virus. Available drugs used for 
treatment include nucleoside reverse transcriptase inhibitors 
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(nrtis), non-nucleoside reverse transcriptase inhibitors 
(nnrtis), protease inhibitors (Pi), and fusion inhibitors. infants 
and children are more susceptible to virological failure with 
the subsequent risk of developing drug resistance, one of the 
major obstacles in antiretroviral (ArV) therapy.2
HiV-1 is divided into four distinct groups: M (major), o (outlier), 
n (non-M non-o or new) and P. the M group is associated with 
global pandemic and has various subtypes (A-D, f-H, J) and 
circulating recombinant forms (crfs).3 the early phase of HiV-1 
epidemic in Malaysia was characterized by the prevalence of 
subtypes crf01_AE and b among heterosexuals and injecting drug 
users (iDU), respectively.4,5 However, in recent years, co-circulation 
and subsequent continual recombination events of crf01_AE and 
subtype b’ (a subtype b variant of thai origin) have formed new 
radiations of novel crfs, including crf33_01b6 and crf15_01b.7
the state of Kelantan is located on the northeastern part of 
peninsular Malaysia and shares a border with thailand on the 
north. Despite its small population of 1.6 million, Kelantan has 
among the highest number of newly reported HiV cases and 
women affected by HiV-AiDs in Malaysia. in many instances, HiV 
transmission in this area starts with infected men transmitting 
the virus to their wives, who in turn transmit it to their children.8
Previous studies on the prevalence of HiV-1 subtypes 
and drug resistance associated mutations in Malaysia were 
conducted mainly in adults. thus, data on HiV-1 infected 
Malaysian children is missing, although HiV drug resistance 
analysis is currently essential to guide ArV therapy strategies. 
this study aimed at analyzing for the first time the circulating 
HiV subtypes and recombinant forms and the magnitude of 
primary mutations associated with ArV drug resistance among 
children who were suspected to have failed their current ArV 
regimens in the east coastal area of Malaysia.
Materials and methods
A total of 30 plasma samples were collected from HiV-1 
infected children who failed treatment at the pediatric clinic 
of the Hospital raja Perempuan Zainab ii (HrPZ ii), Kelantan, 
Malaysia, from May 2009 to December 2010. Patients received a 
combination of at least three ArV agents, including nrtis and 
one nnrti or boosted Pi. Data on patients’ ArV status such as 
cD4+ count, viral load, ArV therapy, and others were collected 
from the patient management database. 5 mL blood samples 
were collected in ethylenediaminetetraacetic acid (EDtA) blood 
collection tubes. Plasma was separated by centrifugation at 
850 g and stored in multiple aliquots at -80° c until used for 
ribonucleic acid (rnA) extraction. this study was approved by 
the Medical research and Ethical committee of the Malaysian 
Ministry of Health (nMrr-08-1390-2886) and by the research 
Ethics committee (Human), Universiti sains Malaysia – UsMKK/ 
PPP/JEPeM (204.3[1]), and an informed consent was obtained 
from all patients prior to sample collection.
HiV-1 rnA was extracted from 140 μL of plasma by column 
purification method (QiAamp Viral rnA Mini Kit, Qiagen – 
Germany), according to the manufacturer’s instructions. reverse-
transcriptase polymerase chain reaction (rt-Pcr) was performed 
using primers bPoL3 (5’-GtGGAAAGGAAGGAcAccAAAtGAA-3’) 
and Prrt2 (5’-GcccAAttcAAtttccccActAAc-3’), which 
involved a reverse transcription step at 50°c for 30 min, 95°c for 
15 min, followed by 35 cycles of 94°c for 30 sec, 55°c for 30 sec, 
and 72°c for 2.5 min, with a final extension step of 10 min at 72°c. 
the rt-Pcr products were then subjected to nested Pcr using 
primers Prrt3 (5’-AcAAGGAActGtAtcctttAGctt-3’) and 
Prrt4 (5’-ttctGtAtGtcAttGAcAGtcc-3’) with the following 
cycling conditions: a denaturation step of 5 min at 94°c, and 
then 40 cycles of 30 sec at 94°c, 30 sec at 55°c, and 2 min at 
72°c, with a final extension at 72°c for 7 min. the polymerase 
chain reaction (Pcr) products were analyzed on 1.5% ethidium 
bromide stained agarose electrophoresis gel. the resulting Pcr-
amplified DnA fragments were purified using a Pcr Product 
Purification Kit (Qiagen – Germany). the nucleotide sequences 
of protease (Pr) and reverse transcriptase (rt) were determined 
by cycle-sequencing dideoxy chain termination method on an 
automated DnA sequencer (Abi PrisM 3100 Genetic Analyzer, 
Applied biosystems – UsA) using two sets of primers, Prrt3/
Prrt4 and r580 (5’-ccttccttttccAtttctGtAcA-3’)/E1PoL1 
(5’-GGAcctAcAcctGtcAAcAt-3’).
sequences were aligned using clustal W, manually edited 
with bioEdit version 7.0.0. the subtypes were determined 
using ncbi Genotyping tools (reference sequence set 2009).9 
resistance-associated mutations were identified using 
stanford’s HiV drug-resistance database genotypic resistance 
interpretation algorithms.10 the association between ArV drug 
and mutation was analyzed by fisher’s exact test (two-tailed), 
with a significance level of 0.05 and a confidence level of 95%.
Results
Among the 30 HiV-1 treated children enrolled in this study, the 
quantitative real-time rt-Pcr results showed that only 21 had 
plasma HiV-1 rnA viral load ≥ 1,000 copies/mL. of those, Pr 
and rt genes were successfully amplified and sequenced in 18 
patients. Detailed information on the baseline characteristics 
of these 18 patients is shown in table 1. the mean HiV-1 viral 
load in this group was log10 4.64 copies/mL with a median of 
log10 4.74 copies/mL. the mean cD4+ count was 234 cells/mm
3, 
 with a median of 144 cells/mm3. the mean duration of ArV 
exposure was 30.7 months with a median of 24.0 months. 
the age range was 3-18 years with nine (50%) males and nine 
(50%) females. fourteen (77.8%) and four (22.2%) patients 
received nrti plus nnrti and nrti plus Pi, respectively. out 
of 12 unsuccessfully amplified samples, one sample had viral 
rnA > 1,000copies/mL, three samples harboured viral rnA at 
< 1000 copies/mL, and eight samples had an unknown viral load.
recombinant crf33_01b (44.4%, 8/18) was found to be the 
predominant HiV subtype, followed by subtypes b in 27.8% 
(5/18), crf15_01b in 16.7% (3/18), and crf01_AE in 11.1% (2/18). 
out of four patients who received Pr therapy, only one child 
had resistance-associated major mutation in the Pr region 
(i84V). Analysis of the rt gene revealed various mutations/
polymorphisms in the nrti region in the majority of children 
at the following positions: t215f/V/Y (66.7%), D67G/n (55.6%), 
K219Q/E/r (44.4%), M184V/i (38.9%), K70r/E (27.8%), M41L 
(27.8%), L75L/M (16.7%), L210W (11.1%), L74i (11.1%), and t69n 
(5.6%). the frequencies of mutations associated with the use 
of nrtis are shown in table 2. the most frequent mutations to 
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Characteristics n (%) Mean (SD) Median (IR)
Gender
 Male 9 (50.0)
 female 9 (50.0)
Ethnicity
 Malay 18 (100.0)
Age (months) 9.9 (4.2) 9 (7)
Viral load (copies/mL)
 ≤ 104 3 (16.7)
 104-105 9 (50.0) 82,458 (85,909.0) 54,850 (92,720)
 ≥ 105 6 (33.3)
cD4+ count (cells/mm3)
 ≤ 50 7 (38.9)
 51-200 3 (16.7) 234 (242.0) 144 (441)
 ≥ 200 8 (44.4)
Duration of ArV exposure (months) 30.7 (24.6) 24 (28)
Antiretroviral regimen
 2 nrti and 1 nnrti 14 (77.8)
 2 nrti and 1 Pi 4 (22.2)   
HiV, human immunodeficiency virus; sD, standard deviation; ArV, antiretroviral; nrti, nucleoside reverse transcriptase inhibitors;  
nnrti, non-nucleoside reverse transcriptase inhibitors; Pi, protease inhibitors.
 NRTI
No. patients/  
mutations
12 
3TC        (%)
12 
AZT        (%)
5 
D4T        (%)
5 
DDI        (%)
1 
TDF        (%)
M41L 1 (8.3) 2 (16.7) 3 (60) 4 (80) 0 (0)
D67Dn/G/n 7 (58.3) 7 (58.3) 2 (40) 2 (40) 1 (100)
t69n 1 (8.3) 0 (0) 0 (0) 0 (0) 1 (100)
K70E/r 4 (33.3) 5 (41.7) 0 (0) 1 (20) 0 (0)
L74i 1 (8.3) 1 (8.3) 1 (20) 1 (20) 0 (0)
V75L/M 2 (16.7) 1 (8.3) 2 (40) 1 (20) 0 (0)
M184i/V 7 (58.3) 7 (58.3) 0 (0) 0 (0) 0 (0)
L210W 0 (0) 1 (8.3) 1 (20) 2 (40) 0 (0)
t215cfsY/f/V/Y 7 (58.3) 7 (58.3) 4 (80) 4 (80) 1 (100)
K219E/Q/r 5 (41.7) 5 (41.7) 2 (40) 2 (40) 1 (100)
 NRTI
No. patients/  
mutations
4 
NVP        (%)
11 
EFV        (%)
A98G 1 (25) 0 (0)
K101E/H/P 0 (0) 5 (45.5)
K103n 1 (25) 8 (72.7)
V106M 0 (0) 1 (9.1)
V108i 1 (25) 1 (9.1)
V179D 0 (0) 1 (9.1)
Y188L 0 (0) 2 (18.2)
G190A 2 (50) 2 (18.2)
P225H 0 (0) 2 (18.2)
P227L 1 (25) 0 (0)
M230L 0 (0) 1 (9.1)
AZt, zidovudine; 3tc, lamivudine; tDf, tenofovir; DDi, didanosine; D4t, stavudine; EfV, efavirenz; nVP, nevirapine; nrti, nucleoside reverse 
transcriptase inhibitors; nnrti, non-nucleoside reverse transcriptase inhibitors.
Table 1 – Baseline characteristics of 18 HIV infected children
Table 2 – Frequency of mutations according to current use of NRTIs and NNRTIs
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nnrti were substitutions at K103n (55.6%), followed by G190A 
(33.3%), K101P/E/H (27.8%), V108i (16.7%), P225H (16.7%), V106M 
(11.1%), Y188L (11.1%), f227L (11.1%), A98G (5.6%), V179D (5.6%), 
and M230L (5.6%). the frequencies of mutations associated 
with the use of nnrtis are shown in table 2.
fisher’s exact test revealed a significant association between 
certain mutations and exposure to nrtis (data not shown). 
significant associations were observed between mutation M184V 
and zidovudine (AZt) resistance (p = 0.038); mutation M184V and 
lamivudine (3tc) resistance (p = 0.038); mutation M41L 
and didanosine (DDi) resistance (p = 0.008); and mutation 
M41L and 3tc resistance (p = 0.022). only one patient (5.6%) had 
no mutation at all in the Pr and rt gene, while 94.4% patients 
had resistance mutations to both nrti and nnrti.
Discussion
Although the rate of HiV infections has declined in southeast 
Asia in recent years, HiV/AiDs still poses a serious public health 
problem, with children being the most vulnerable group.1 this 
study provides the first report on circulating HiV subtypes 
and recombinant forms, and mutations associated with ArV 
resistances among HiV-1 children who failed treatment in 
the east coastal area of Malaysia, which is located next to 
thailand, the country with the highest incidence of HiV/AiDs 
in southeast Asia.
in this study, recombinant crf33_01b (44.4%) was found to be 
the predominant HiV subtype, followed by subtypes b in 27.8%, 
crf15_01b in 16.7%, and crf01_AE in 11.1% in children failing 
treatment in Kelantan, Malaysia. the results support the recent 
findings on the emergence of new predominant HiV subtypes/
crfs circulating in Malaysia, demonstrating the dynamic and 
rapid evolution of HiV. in the early HiV pandemic, subtypes b 
and crf01_AE were the major subtypes found in Malaysia. An 
initial report showed that there was an almost equal prevalence 
of subtype b (50%) and crf_AE/b recombinant (41.7%) among iDU 
in Kuala Lumpur, Malaysia.11 However, in the following years, 
various studies performed on HiV-1 patients in Kuala Lumpur 
reported a predominance of subtype crf01_AE (65-86%) over 
subtype b (8.3-14%).6,12-14 in addition, the emergence of second 
generation derivatives resulting from co-circulation of crf01_
AE and subtype b, crf33_01b, as well as other Urfs, were also 
reported in these studies, albeit at lower prevalence. interestingly, 
the present study, which attempted for the first time to describe the 
molecular epidemiology of HiV-1 among children in Kelantan, 
showed that crf33_01b has emerged as the predominant 
circulating subtype in the state. the higher prevalence of 
crf33_01b and lower prevalence of crf01_AE demonstrated in 
this study is in accordance with a recent proposition regarding 
a possible gradual reduction of the current predominance of 
crf01_AE and greater distribution of crf33_01b in Malaysia.15 
only one major mutation (i84V) associated with Pi was 
observed in a patient. in contrast, most of these children carried 
mutations to nrtis and nnrtis at higher frequencies. the 
mutation rate of resistance to both nrti and nnrti was 94.4%, 
with the most frequent mutations including types t215f/Y/V, 
D67G/n, M184V/i, and K219Q/E/r (nrti), and K103n (nnrti). 
the higher frequencies of resistance mutations observed in 
rt than in Pr shown in the present study are similar to those 
previously reported in Kuala Lumpur,6 thailand16,17 and india18 
(rt resistant > Pr resistant). it is possible that the acquisition of 
resistance mutations in Pr is difficult because most of the sites 
in Pr are under strong selection, making it less susceptible to 
resistance mutations.18 Alternatively, the lower frequencies of 
mutation in Pr observed in many studies, including the present 
study, could be due to a more widespread use of double nrti 
with nnrti rather than with Pi as the first line regimen of 
treatment in patients. 
 Extensive drug resistance to nrtis, nnrtis, and Pi in HiV-
1-infected children is a global phenomena observed in various 
studies, leaving these children with limited choice of ArV drugs 
for their second line or salvage therapy.19,20 Almeida et al. 
observed HiV resistance to nrtis, nnrtis, and Pis in 96%, 61%, 
and 17% of 23 ArV-experienced children in são Paulo, brazil, 
respectively.20 the rt mutation K103n was the most commonly 
occurring nnrti-resistance mutation observed in the current 
study. K103n is associated with resistance to efavirenz, the main 
nnrti used in these children. An almost universal presence of 
nrti resistance mutations, particularly t215Y/f, M184V/i, D67n, 
M41L, and K219Q/E was detected among children receiving ArV 
therapy in são Paulo, brazil, a finding similar to this study’s.20 
interestingly, contrary to a report on the presence of nrti 
resistance mutation, Q151M, in 5% of HiV-1 infected thailand 
children,16 this clinically important mutation was not found in 
the present study. A Q151M multi-drug resistance complex is 
composed of the Q151M mutation, which is normally the first to 
appear, followed by at least two of the following four mutations: 
A62V, V75i, f77L, and f116Y. the Q151M MDr confers resistance 
to almost all nrtis with the exception of tenofovir, rendering 
nrti therapy ineffective in patients with this mutation.19
in conclusion, the emergence of crf33_01b as the 
predominant HiV-1 subtype among children who failed ArV 
therapy in Kelantan, Malaysia, is reported in this study, an 
observation not previously described. furthermore, a high 
frequency of major mutations associated with resistance 
to ArV drugs in these children was described. Although the 
sample size analyzed in this study was rather small, reflecting 
the smaller number of HiV-1 infections in children and perhaps 
warranting further investigation, the results are still invaluable 
as they provide pertinent information on the presence of 
various HiV-1 subtypes and the status of HiV-1 drug-resistance 
in this area. it remains to be investigated whether or not 
similar HiV-1 subtypes and ArV drug resistance patterns 
would be observed in adults in Kelantan.
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